Abstract
1. The effect of ketanserin on digital blood flow and 5-hydroxytryptamine (5-HT)-induced platelet aggregation was studied in 18 patients with Raynaud's phenomenon. 2. Measurements were made before and after a single dose of 20 mg ketanserin and again after 1 month of continuous treatment with 20 mg ketanserin three times a day. 3. Digital blood flow was assessed by changes in digital pulse volume; platelet aggregation by changes in light transmission after challenge with 10(-5) M 5-HT. 4. Ketanserin induced a rise in digital blood flow and blocked the platelet response to 5-HT; the two events were not correlated and were independent of subjective improvement. 5. These data do not support the suggestion that 5-HT2-receptor blockade is of major importance in the dilatory effect of ketanserin in Raynaud's phenomenon.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Amstein R., Fetkovska N., Pletscher A., Bühler F. R. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin. J Hypertens. 1989 Apr;7(4):255–260. [PubMed] [Google Scholar]
- Arneklo-Nobin B., Owman C. Adrenergic and serotoninergic mechanisms in human hand arteries and veins studied by fluorescence histochemistry and in vitro pharmacology. Blood Vessels. 1985;22(1):1–12. [PubMed] [Google Scholar]
- Blauw G. J., van Brummelen P., Chang P. C., Vermeij P., van Zwieten P. A. 5HT3 receptor-mediated vasodilation in the human forearm. J Hypertens Suppl. 1988 Dec;6(4):S33–S35. doi: 10.1097/00004872-198812040-00006. [DOI] [PubMed] [Google Scholar]
- Blauw G. J., van Brummelen P., Chang P. C., Vermeij P., van Zwieten P. A. Regional vascular effects of serotonin and ketanserin in young, healthy subjects. Hypertension. 1988 Mar;11(3):256–263. doi: 10.1161/01.hyp.11.3.256. [DOI] [PubMed] [Google Scholar]
- Brouwer R. M., Wenting G. J., Visser W., Schalekamp M. A. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon? Vasa Suppl. 1987;18:64–67. [PubMed] [Google Scholar]
- Coffman J. D., Clement D. L., Creager M. A., Dormandy J. A., Janssens M. M., McKendry R. J., Murray G. D., Nielsen S. L. International study of ketanserin in Raynaud's phenomenon. Am J Med. 1989 Sep;87(3):264–268. doi: 10.1016/s0002-9343(89)80148-2. [DOI] [PubMed] [Google Scholar]
- Coffman J. D., Cohen R. A. Alpha-adrenergic and serotonergic mechanisms in the human digit. J Cardiovasc Pharmacol. 1988;11 (Suppl 1):S49–S53. [PubMed] [Google Scholar]
- Lijnen P., Fagard R., Staessen J., Vanhees L., Amery A. Mechanism of hypotensive action of ketanserin in men. Eur Heart J. 1987 Mar;8(3):308–312. doi: 10.1093/oxfordjournals.eurheartj.a062274. [DOI] [PubMed] [Google Scholar]
- Longstaff J., Gush R., Williams E. H., Jayson M. I. Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon. J Cardiovasc Pharmacol. 1985;7 (Suppl 7):S99–101. doi: 10.1097/00005344-198500077-00028. [DOI] [PubMed] [Google Scholar]
- Marasini B., Biondi M. L., Bianchi E., Dell'Orto P., Agostoni A. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon. Eur J Clin Pharmacol. 1988;35(4):419–421. doi: 10.1007/BF00561375. [DOI] [PubMed] [Google Scholar]
- Rodnan G. P., Myerowitz R. L., Justh G. O. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980 Nov;59(6):393–408. doi: 10.1097/00005792-198011000-00001. [DOI] [PubMed] [Google Scholar]
- Stranden E., Roald O. K., Krohg K. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin. Br Med J (Clin Res Ed) 1982 Oct 16;285(6348):1069–1071. doi: 10.1136/bmj.285.6348.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vanhoutte P. M. Vascular physiology: the end of the quest? Nature. 1987 Jun 11;327(6122):459–460. doi: 10.1038/327459a0. [DOI] [PubMed] [Google Scholar]